Business Context and Reporting Period
Absci Corp (ABSI) filed a Form 8-K on February 27, 2024, disclosing preliminary unaudited financial highlights for the three months and year ended December 31, 2023. The company operates an AI-driven platform for creating biologic drug candidates through a dual-faceted model: partnerships with pharmaceutical companies and internal asset development.
Key Financial Metrics
- Liquidity: As of December 31, 2023, the company held approximately $97.7 million in unrestricted cash, cash equivalents, and short-term investments.
- Revenue: Preliminary estimates indicate revenue of approximately $0.3 million for the three months ended December 31, 2023, and $5.7 million for the full year.
- Operating Expenses: Estimated at $24 million to $26 million for the three months ended December 31, 2023, and $120 million to $122 million for the full year.
- Profitability: The filing does not provide a specific net loss figure, but operating expenses significantly exceed revenue, indicating a net loss for the periods.
- Debt: The filing text does not provide specific values for long-term or short-term debt.
Material Changes and Unusual Items
The operating expense estimates for the full year 2023 include a $21.3 million goodwill impairment charge that was recorded in the second quarter of 2023 (ended June 30, 2023). The company notes that actual results may differ from these preliminary estimates as final closing procedures and audits are completed.
Guidance, Outlook, and Risks
Business Model Evolution: Absci is diversifying its portfolio by balancing partnered drug creation programs with internal asset development to manage risk and maximize economic returns.
Pipeline Updates:
- Active Programs: As of December 31, 2023, there are 16 active programs with partners including PrecisionLife, Almirall, AstraZeneca, and Merck.
- Internal Assets: Three wholly-owned internal programs are identified: ABS-101 (inflammatory bowel disease), ABS-201 (dermatology), and ABS-301 (immuno-oncology).
- ABS-101 Timeline: IND-enabling studies were initiated in February 2024. The company plans to submit an Investigational New Drug (IND) application in Q1 2025 and potentially initiate a Phase 1 trial in the first half of 2025.
Capital Markets: On February 27, 2024, the company filed a preliminary prospectus supplement for a proposed registered underwritten public offering of common stock.
Risks: The filing includes standard forward-looking statement disclaimers regarding the uncertainty of financial estimates, the success of drug development, regulatory approvals (FDA), and the ability to secure future funding or partnerships.
Investor Verification Checklist
- Verify the final audited financial results in the upcoming Form 10-K to confirm the preliminary revenue and expense estimates.
- Monitor the progress of the proposed public offering of common stock and its impact on share dilution.
- Track the timeline for the ABS-101 IND submission (Q1 2025) and subsequent Phase 1 trial initiation.
- Review the status of the 16 active partnership programs to assess potential future milestone payments and royalties.
- Confirm the company's cash burn rate relative to the $97.7 million liquidity position to evaluate runway.